Author | Robert Doebele, MD

Articles

Newer Targeted Agents in NSCLC: TAK-788, an EGFR and HER2 Inhibitor

June 18, 2018

Robert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.